TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Childhood Social Phobia
Brief Summary: This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
B: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
C: Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Childhood Social Phobia
Brief Summary: This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.


Options:
A: Arm Label: 1. Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: 2. Client Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1. Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2. Client Centered Therapy
B: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT
C: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
D: Arm Label: Cognitive-Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Wait-list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Cognitive-Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
C: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.


Options:
A: Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
C: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.


Options:
A: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: Risperidone, Intensive; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: risperidone, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: olanzapine, intensive; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: olanzapine, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: aripiprazole, intensive; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: aripiprazole, basiv; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone, Intensive, risperidone, basic | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, basic, olanzapine, intensive | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): aripiprazole, basiv, aripiprazole, intensive
C: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
D: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.


Options:
A: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
B: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
C: Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abilify | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidal Consta | Intervention Type: DRUG; Name: Abilify; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidal Consta; Assigned to Arm(s): 001
D: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.


Options:
A: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
B: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention
C: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
D: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.


Options:
A: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
B: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A
D: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Brief Summary: The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression


Options:
A: Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care
B: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
C: Arm Label: Mindfulness-based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Cognitive Therapy, Biological: Standard psychiatric care | Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy, Biological: Standard psychiatric care | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard psychiatric care | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Cognitive Therapy; Assigned to Arm(s): Mindfulness-based Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: The Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BIOLOGICAL; Name: Standard psychiatric care; Assigned to Arm(s): CBASP, Mindfulness-based Cognitive Therapy, Treatment-as-usual
D: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Brief Summary: The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression


Options:
A: Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Desvenlafaxine succinate sustained release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine succinate sustained release 50 mg, Drug: Desvenlafaxine succinate sustained release 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 50 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 25 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
D: Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)

Answer: C